With Parity Pricing, Gilead Relies On Genvoya Safety To Convert From Stribild
This article was originally published in The Pink Sheet Daily
Executive Summary
Genvoya includes a much smaller dose of tenofovir than Stribild, allowing for smaller pills, while its label also includes a number of safety advantages that Gilead can use in marketing.
You may also be interested in...
Gilead HIV Sales Getting Boost From Switches To TAF-Based Combos
Eighty percent of patients who’ve received Genvoya so far are switched over from older Gilead regimens, while 10% have switched from non-Gilead drugs. In terms of cumulative prescriptions, the Genvoya launch is outpacing the launch of predecessor drug Stribild to date.
When Will Gilead Make Its M&A Move?
While HCV sales continue to slow due to a lengthy list of factors, Gilead is seeing a strong launch for revised HIV combo therapies incorporating TAF – but most analysts believe that major M&A is needed to offset stagnation.
2Q Pharma Results Preview: What Lies Ahead
The big pharma financial reporting season gets underway on July 19 with Novartis and Johnson & Johnson in the vanguard. Biosimilar threats to immunology and cancer drugs and new product ramp-ups are among the key things to watch for as results are announced.